API | filanesib

filanesib Report issue

Small molecule Experimental

AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW

Filanesib is a kinesin spindle protein (KIF11) inhibitor which has recently been proposed as a cancer treatment, specifically for multiple myeloma. ^Wikipedia

Chemistry

SMILES: CON(C)C(=O)N1N=C(c2cc(F)ccc2F)S[C@@]1(CCCN)c1ccccc1
InChIKey: LLXISKGBWFTGEI-FQEVSTJZSA-N
Mol. Mass: 420.49
ALogP: 3.88 Partition coefficient
ChEMBL Molecule:
filanesib

More Chemistry

Pharmacology

Mechanism of Action:
- Kinesin-like protein KIF11 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

arry 520 | arry-520 | filanesib

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Leukemia, Plasma Cell (Phase 1/Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Neoplasms (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue